iCAD, Inc. (Nasdaq: ICAD) an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced it has been added to the Russell Microcap(R) Index when the Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes on June 22. iCAD, Inc. offers a range of CAD products to enhance the early identification of cancer. SecondLook(R), approved by the FDA in 2002, provides a computerized second review of both screening and diagnostic mammograms. TotalLook(R), introduced by iCAD at the end of 2005, provides customers with a comprehensive film-to-digital solution making it easier for women's health centers to transition from film to digital mammography. This technology assists radiologists in comparing breast images year-to-year to detect subtle changes that may be indicative of breast cancer.

Anybody -- Is NSTK a buy at present levels ? my daughter wants to dip her toe in the market and i am a newbie myself. would appreciate the opinion of more experienced contributors. thanks in advance. pixy242 Asked by pixy242 - Bookmark this User - 2 answers - 111 views - Ignore this user 3 hours ago - Bookmark this question - Report Abuse Answer this question Previous1NextI totally agree with this answer. it is highly speculative but it is working on the three most important issues out there: diabetes, obesity and autism and it has an rnai possibiilty. I am getting a lot of heat from the shorts for recommending this one. I like that... Answered by Jim Cramer - Bookmark this User - Ignore this user 2 hours ago - Report Abuse Rate Now: Average Rating: 0.00 / 0 ratings If this is a "dipping the toe in the market" sort of play I wouldn't do it. ITs highly speculative and there's no way to really game what can happen. I would only use a small portion of portfolio on a spec play like this. However, as far as biotech plays go this has several things going for it. - they have a lot of potential drugs in the FDA pipeline so its diversified on product line. - they have shown an ability to partner with larger players (PG, for instance on their parathyroid hormone nasal spray) - they have about 18 months or more cash in the bank so if they can partner with other players they might be able to extend the runway. - they are in an innovative field (RNAi) where, if it works out, will make them a multi-billion company Here are the negatives: - any bad FDA result will send this stock tumbling down - they will probably do a dilutive financing at some point. The ideal would be that that point is at much higher levels. I like it just because of their innovative research and ability to find larger partners. But I view it as an option on biotech rather than an investment and would treat it in a portfolio as such (i.e. small). If she wants to dip her toe in the waters I would focus on safer stocks than this one. Answered by James Altucher - Bookmark

SO IM GOING TO ASK AGIN AND MAYBE SOMEONE CAN HELP ME OUT WITH AN ANSWER. I OWN SHARES IN AGIX AND IM WONDERIN WHAT IS MY MOVE AFTER ITS SEPT.5TH ANNOUNCEMENT ABOUT ITS NEW DRUG???? SHOULD I SELL AN AMOUNT OF SHARES BEFORE THE ANNOUNCEMENT TO PROTECT MYSELF FROM A LOSS DUE TOO BAD NEWS? HELLLP? LOL THANX TO WHOEVER HELPS... IM OUT FOR NOW... NEWBIE Asked by hapa808 - Bookmark this User - 5 answers - 57 views - Ignore this user 1 hour ago - Bookmark this question - Report Abuse Answer this question Previous1NextSorry I forgot to put the source...this is the second time today..to much clorine and bbq I guess. Source(s): Wall Street Jounal. Answered by Trading Nymph 2 seconds ago Rate Now: Average Rating: 0.00 / 0 ratings Ok..I may be wrong..but here is my take..as you can see below this was a heart med that they were testing and then they found out it lowered blood sugar...so they said hey...let's work on testing the drug for that use. At this point they have started to test in Phase 3...once they complete phase 3 then they can go to the FDA and stand in line for approval...that is not happening on Sept 5th..it may be a year or two depending on the testing. The Company is going to speak to the ESC..European Society of Cardiology..or Heart Docs...and the topic will cover the use of the Medication to reduce inflamation in Cardiac Patients and oh yes it lowers blood sugar too. They just started phase 3 so there really is no new data, only the old data that says 2,200 patients who were diabetic seem to have their blood sugar lowered. Biotechs like these I call Lottery Tickets..there is no earnings and if the drug does not make FDA approval, the stock could go to zero..but if FDA says yes then it will fly for that day and everyone on TV will suddenly become experts on it..even though they never heard about before. So my call, you will probably get a bounce up on Wed. because the wires may cover it...if you don't want to hold your lottery ticket for a months or years..sell on that bounce...it will probably drift down after everyone forgets about it..and you can buy it back. Or just stick it in your back pocket and wait...thank you for this question..I have a biotech portfolio here and I am going to add this to it..btw I myself would give it a few months and follow it to see that there is no more liver problems...but remember the wrong part. Source(s): Last we heard, AGI-1067 (also known as succinobucol) was a drug for patients who had been hospitalized because of a heart attack or unstable chest pain. But it failed to meet its primary goal in a study of those patients, and AstraZeneca, which had been working with AtheroGenics on the drug, abandoned the project. We did a little looking and realized we’d missed this announcement from a couple months back that said AGI-1067 had become a diabetes drug, based on a finding from the study of heart patients that the drug lowered blood sugar in patients with diabetes. And just last week, the company said it had started enrolling patients in a diabetes trial. Diabetes is certainly a big market, but it’s worth keeping in mind that in the trial of heart patients (which will be the source of the data presented next week), one patient developed liver failure, which went away after the drug was stopped. Answered by Trading Nymph

sorry, my question was about cardica (CRDC) part of my msg was omitted -- it traded 1.5 x outstanding shares on thursday and very high on wed and fri. pixy242 Asked by pixy242 - Bookmark this User - 1 answers - 16 views - Ignore this user 1 hour ago - Bookmark this question - Report Abuse Answer this question Previous1NextNot sure what the full question was. But CRDC was a biotech that hit the lottery...can you imagine that they have a product that can make bypass heart surgery a bandage and a lollipop procedure...so totally cool. Source(s): PR FIrst Call 9/5 For the first time during a totally endoscopic coronary artery bypass procedure, Marc R. Katz, M.D. and his team at Bon Secours Saint Mary's Hospital in Richmond, Virginia used the C-Port Flex A system to connect a bypass graft, to the left anterior descending (LAD) artery. The patient was released from the hospital two days following the minimally-invasive bypass procedure and already is participating in routine daily activities. Answered by Trading Nymph 9 seconds ago